Quick Answer
Lipocine Inc. reported Total Revenue of $1.98 million for the year ending 2025.
- Lipocine Inc. showed a decrease of -82.3% in Total Revenue from 2024 to 2025.
- This data is from Lipocine Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: $0.00 | Q3 2012: $0.00 | Q3 2013: $0.00 | Q1 2017: $0.00 | Q2 2017: $0.00 | Q3 2017: $0.00 | Q1 2018: $428.0 thousand | Q2 2018: $0.00 | Q3 2018: $0.00 | Q4 2018: $0.00 | Q1 2019: $0.00 | Q2 2019: $0.00 | Q3 2019: $165.0 thousand | Q3 2020: $0.00 | Q3 2021: $55.0 thousand | Q2 2022: $500.0 thousand | Q1 2023: $55.0 thousand | Q1 2023: $55.0 thousand | Q3 2023: -$3.12 million | Q1 2024: $7.62 million | Q2 2024: $89.6 thousand | Q1 2025: $93.9 thousand | Q2 2025: $622.8 thousand | Q3 2025: $114.6 thousand.
- Over the full 14 years of available data (2012 to 2025), Lipocine Inc.'s Total Revenue has declined by 74.4%.
- Historical annual values: Fiscal year 2025: $1.98 million | Fiscal year 2024: $11.20 million | Fiscal year 2023: -$2.85 million | Fiscal year 2022: $500.0 thousand | Fiscal year 2022: $500.0 thousand | Fiscal year 2021: $16.14 million | Fiscal year 2021: $16.14 million | Fiscal year 2020: $0.00 | Fiscal year 2019: $165.0 thousand | Fiscal year 2018: $428.0 thousand | Fiscal year 2017: $0.00 | Fiscal year 2016: $0.00 | Fiscal year 2013: $0.00 | Fiscal year 2012: $7.71 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: